Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

vir biotechnology inc. - VIR

VIR

Close Chg Chg %
6.95 0.17 2.45%

Closed Market

7.12

+0.17 (2.45%)

Volume: 891.74K

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: vir biotechnology inc. - VIR

VIR Key Data

Open

$6.97

 Day Range

6.88 - 7.27

52 Week Range

6.56 - 13.05

 Market Cap

$957.15M

Shares Outstanding

137.72M

 Public Float

87.31M

Beta

0.46

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.92

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.52M

  

VIR Performance

1 Week
 
 -11.11%
 
1 Month
 
 -4.81%
 
3 Months
 
 -18.81%
 
1 Year
 
 -27.05%
 
5 Years
 
 -44.33%
 

VIR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About vir biotechnology inc. - VIR

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

VIR At a Glance

Vir Biotechnology, Inc.
1800 Owens Street
San Francisco, California 94158
Phone 1-415-906-4324 Revenue 86.18M
Industry Biotechnology Net Income -615,061,000.00
Sector Health Technology Employees 587
Fiscal Year-end 12 / 2024
View SEC Filings

VIR Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 15.657
Price to Book Ratio 0.853
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.096
Enterprise Value to Sales -0.717
Total Debt to Enterprise Value -2.016

VIR Efficiency

Revenue/Employee 146,814.31
Income Per Employee -1,047,804.089
Receivables Turnover 7.429
Total Asset Turnover 0.034

VIR Liquidity

Current Ratio 9.055
Quick Ratio 9.055
Cash Ratio 8.755

VIR Profitability

Gross Margin 74.221
Operating Margin -767.005
Pretax Margin -728.932
Net Margin -713.693
Return on Assets -24.544
Return on Equity -33.535
Return on Total Capital -35.868
Return on Invested Capital -31.512

VIR Capital Structure

Total Debt to Total Equity 7.832
Total Debt to Total Capital 7.263
Total Debt to Total Assets 6.354
Long-Term Debt to Equity 7.022
Long-Term Debt to Total Capital 6.512
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Vir Biotechnology Inc. - VIR

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
76.37M 1.10B 1.62B 86.18M
Sales Growth
+843.86% +1,334.39% +47.51% -94.67%
Cost of Goods Sold (COGS) incl D&A
- 71.68M 161.81M 22.22M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
8.81M 11.98M 15.49M 19.45M
Depreciation
7.77M 11.45M 14.96M 18.92M
Amortization of Intangibles
1.04M 533.00K 532.00K 531.00K
COGS Growth
- - +125.75% -86.27%
-
Gross Income
- 1.02B 1.45B 63.96M
Gross Income Growth
- - +42.03% -95.60%
-
Gross Profit Margin
- +93.46% +89.99% +74.22%
2020 2021 2022 2023 5-year trend
SG&A Expense
363.70M 602.99M 620.92M 724.97M
Research & Development
296.14M 442.19M 467.87M 550.92M
Other SG&A
67.57M 160.79M 153.05M 174.05M
SGA Growth
+105.40% +65.79% +2.97% +16.76%
Other Operating Expense
- - - -
-
Unusual Expense
832.00K (138.05M) 111.14M 45.19M
EBIT after Unusual Expense
(296.98M) 558.80M 721.93M (706.19M)
Non Operating Income/Expense
(1.63M) (9.00M) 32.35M 78.00M
Non-Operating Interest Income
2.84M 439.00K 28.09M 86.99M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(298.61M) 549.80M 754.28M (628.19M)
Pretax Income Growth
-71.10% +284.12% +37.19% -183.28%
Pretax Margin
-391.02% +50.19% +46.68% -728.93%
Income Tax
54.00K 21.22M 238.44M (13.08M)
Income Tax - Current - Domestic
- 3.63M 240.98M (12.09M)
Income Tax - Current - Foreign
106.00K 2.40M 12.65M 75.00K
Income Tax - Deferred - Domestic
(52.00K) 15.19M (15.19M) (1.00M)
Income Tax - Deferred - Foreign
- - - (59.00K)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(298.67M) 528.58M 515.84M (615.12M)
Minority Interest Expense
- - - (56.00K)
-
Net Income
(298.67M) 528.58M 515.84M (615.06M)
Net Income Growth
-70.98% +276.98% -2.41% -219.24%
Net Margin Growth
-391.09% +48.25% +31.92% -713.69%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(298.67M) 528.58M 515.84M (615.06M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(298.67M) 528.58M 515.84M (615.06M)
EPS (Basic)
-2.5064 4.0696 3.89 -4.5855
EPS (Basic) Growth
-54.46% +262.37% -4.41% -217.88%
Basic Shares Outstanding
119.16M 129.88M 132.61M 134.13M
EPS (Diluted)
-2.5064 3.9613 3.8264 -4.5855
EPS (Diluted) Growth
-54.46% +258.05% -3.41% -219.84%
Diluted Shares Outstanding
119.16M 133.44M 134.81M 134.13M
EBITDA
(287.33M) 432.73M 848.56M (641.55M)
EBITDA Growth
-70.04% +250.60% +96.09% -175.61%
EBITDA Margin
-376.25% +39.50% +52.52% -744.43%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 29.875
Number of Ratings 9 Current Quarters Estimate -0.872
FY Report Date 12 / 2024 Current Year's Estimate -3.927
Last Quarter’s Earnings -1.56 Median PE on CY Estimate N/A
Year Ago Earnings -4.59 Next Fiscal Year Estimate -3.807
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 4 9 9
Mean Estimate -0.87 -0.79 -3.93 -3.81
High Estimates -0.66 -0.68 -3.70 -2.75
Low Estimate -0.96 -0.92 -4.02 -5.28
Coefficient of Variance -11.16 -12.66 -2.40 -19.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 1 1 1
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Vir Biotechnology Inc. - VIR

Date Name Shares Transaction Value
Nov 19, 2024 Jason V. O’Byrne EVP & Chief Financial Officer 150,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 19, 2024 Jason V. O’Byrne EVP & Chief Financial Officer 75,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Vanina de Verneuil EVP and General Counsel 56,973 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.11 per share 575,997.03
Jul 17, 2024 Mark D. Eisner EVP and Chief Medical Officer 75,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 17, 2024 Mark D. Eisner EVP and Chief Medical Officer 150,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 13, 2024 Marianne de Backer Chief Executive Officer; Director 53,118 Other acquisition or disposition 0.00
Jun 13, 2024 Marianne de Backer Chief Executive Officer; Director 625,339 Other acquisition or disposition 0.00
Jun 12, 2024 Sona Saira Ramasastry Director 14,619 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.95 per share 160,078.05
Jun 3, 2024 Vicki L. Sato Director 16,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 George A. Scangos Director 120,989 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Vicki L. Sato Director 1,323,351 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Robert Taylor Nelsen Director 16,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Jeffrey S. Hatfield Director 23,806 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Jeffrey S. Hatfield Director 16,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Sona Saira Ramasastry Director 16,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Janet Ann Napolitano Director 23,806 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Janet Ann Napolitano Director 16,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Robert Taylor Nelsen Director 584,148 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Robert J. More Director 16,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 3, 2024 Robert J. More Director 46,683 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Vir Biotechnology Inc. in the News